Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Launches its EpiSwitch Covid-19 Severity Test in the US. Notes the prognostic test can identify high-risk individuals who, if exposed to the Covid-19 virus, are likely to experience severe complications and potentially require hospitalisation. Says the EpiSwitch test results will better enable physicians and at-risk individuals to form effective healthcare management plans.
"Even with advanced national vaccination programs underway, millions of people, 10 million in the US alone, remain exposed to the risk of severe Covid disease because they are immunocompromised, immunosuppressed or for other medical reasons cannot be vaccinated. Understanding their individual risk will enable them and their physicians to formulate a proactive healthcare plan, and ensure they take appropriate infection mitigation measures," says Chief Executive Jon Burrows.
Current stock price: 116.00 pence
Year-to-date change: up 67%
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oxford Biodyn (OBD)